Lexapro and Monoclonal gammopathy - a phase IV clinical study of FDA data

Summary:

Monoclonal gammopathy is reported as a side effect among people who take Lexapro (escitalopram oxalate), especially for people who are female, 50-59 old, also take Zometa, and have Multiple myeloma.

The phase IV clinical study analyzes which people have Monoclonal gammopathy when taking Lexapro. It is created by eHealthMe based on reports of 82,231 people who have side effects when taking Lexapro from the FDA, and is updated regularly.

What is Lexapro?

Lexapro has active ingredients of escitalopram oxalate. It is often used in depression. eHealthMe is studying from 91,464 Lexapro users. Check the latest studies of Lexapro.

What is Monoclonal gammopathy?

Monoclonal gammopathy is found to be associated with 210 drugs and 234 conditions by eHealthMe. Check the latest studies of Monoclonal gammopathy.

On Jul, 12, 2026

82,231 people reported to have side effects when taking Lexapro.
Among them, 25 people (0.03%) have Monoclonal gammopathy.

Could Lexapro cause Monoclonal gammopathy?

Among these 25 people:

What is the gender of people who have Monoclonal gammopathy when taking Lexapro? *

female: 100 %
male: 0.0 %

What is the age of people who have Monoclonal gammopathy when taking Lexapro? *

What are other drugs people take besides Lexapro? *

What are other side effects people have besides Monoclonal gammopathy? *

Anaemia (lack of blood): 25 people, 100.00%
Pain: 24 people, 96.00%
Chest Pain: 23 people, 92.00%
Hypoaesthesia (reduced sense of touch or sensation): 23 people, 92.00%
General Physical Health Deterioration (weak health status): 23 people, 92.00%
Neuropathy Peripheral (surface nerve damage): 23 people, 92.00%
Exposed Bone In Jaw: 23 people, 92.00%
Spinal Osteoarthritis (joint cartilage loss in spine): 23 people, 92.00%
Osteonecrosis Of Jaw (death of bone of jaw): 23 people, 92.00%
Weight Loss: 22 people, 88.00%

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 22 people, 88.00%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 2 people, 8.00%
Paraproteinaemia (normal or abnormal plasma protein appearing in large quantities): 1 person, 4.00%
High Blood Pressure: 1 person, 4.00%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 4.00%

* Approximation only. Some reports may have incomplete information.

Do you take Lexapro and have Monoclonal gammopathy?

- Check whether Monoclonal gammopathy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lexapro:

Lexapro (91,464 reports)

Browse all side effects of Lexapro:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Monoclonal gammopathy:

Monoclonal gammopathy (210 drugs)

Browse all the conditions that are associated with Monoclonal gammopathy:

Monoclonal gammopathy (234 conditions)

Related publications that referenced our studies

O’Brien FE, O’Connor RM, Clarke G, Donovan MD, Dinan TG, Griffin BT, Cryan JF, "The P-glycoprotein inhibitor cyclosporin A differentially influences behavioural and neurochemical responses to the antidepressant escitalopram", Behavioural brain research, 2014 Mar .
O’Brien FE, O’Connor RM, Clarke G, Donovan MD, Dinan TG, Griffin BT, Cryan JF, "The P-glycoprotein inhibitor cyclosporin A differentially influences behavioural and neurochemical responses to the antidepressant escitalopram", Behavioural brain research, 2014 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on escitalopram oxalate (the active ingredients of Lexapro) and Lexapro (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.